Ningbo Menovo Pharmaceutical Co (SHSE:603538) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603538 Ningbo Menovo Pharmaceutical Co Ltd SHSE:603538
73 GF Score
Price ¥27.20
GF Value ¥17.65
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Ningbo Menovo Pharmaceutical Co Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Ningbo Menovo Pharmaceutical Co Quality Rank Related Terms

SHSE:603538
73GF Score
Ningbo Menovo Pharmaceutical Co Ltd SHSE:603538
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ningbo Menovo Pharmaceutical Co (SHSE:603538) Overvalued in 2026?

Based on GuruFocus' analysis, Ningbo Menovo Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥27.20 is trading 54.1% above its estimated GF Value™ of ¥17.65. GuruFocus considers Ningbo Menovo Pharmaceutical Co to be Significantly Overvalued.

Key valuation signals for SHSE:603538:

  • Quality Rank:
  • GF Value™: ¥17.65 vs. price of ¥27.20 (54.1% above fair value)
  • GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the SHSE:603538 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ningbo Menovo Pharmaceutical Co Business Description

Address No.999,Yangfan Road, Room 1406, No.1, High-tech Zone, Ningbo, CHN, 315040
Ningbo Menovo Pharmaceutical Co Ltd is a China-based company is engaged in the research and development, pilot, production and sales of pharmaceutical intermediates, APIs and finished drugs. Its products line includes cardiovascular, central nervous, respiratory, anti-tumor, anti-infective, digestive system, geriatric diseases and anti-viral systems.
73GF Score

Get the complete analysis for SHSE:603538

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥27.20
Price
¥17.65
GF Value